The antiviral activity of several nucleoside analogues is often limited by their rapid degradation by pyrimidine nucleoside phosphorylases. In an attempt to avoid this degradation, several modified nucleosides have been synthesized. A series of 4h-thio2h-deoxyuridines exhibits an anti-[herpes simplex virus (HSV)] activity significantly higher (20-600 times) than that shown by the corresponding 4h-oxy counterpart. We investigated the mode of action of these compounds and we found that : (i) several 4h-thio-2h-deoxyuridines are phosphorylated to the mono-and diphosphates by HSV-1 thymidine kinase (TK) more efficiently than their corresponding 4h-oxy counterpart ; (ii) both are inhibitors of cellular thymidylate synthase ; (iii) 4h-thio-2h-deoxyuridines are resistant to phosphorolysis by human thymidine phosphorylase ; (iv) both 4h-oxy-and 4h-thio-2h-deoxyuridines are phosphorylated to deoxyribonucleotide triphosphate in HSV-1-infected cells and are incorporated into viral DNA ; (v) 4h-thio-
INTRODUCTION
The antiviral activity of 5h-bromovinyl-2h-deoxyuridine (BVdU) and similar analogues is often limited by their rapid degradation by pyrimidine nucleoside phosphorylases, which cleave the glycosidic bond between the pyrimidine ring and the sugar moiety. In an attempt to avoid this degradation, modified nucleosides, such as carbocyclic derivatives [1, 2] , have been synthesized in which the sugar moiety has been replaced by a cyclopentyl or a cyclobutyl ring, or enantiomeric derivatives [3, 4] , in which the -deoxyribose moiety has been replaced by the  enantiomer [3] [4] [5] [6] . More recently, several 4h-thio-2h-deoxyribonucleosides have been synthesized and studied for their possible antiviral activity [7] . We show here that the anti-herpetic activity of a large series of these derivatives, whose chemical structures are reported in Table 1 , is always significantly higher than that of the corresponding 4h-oxy derivatives. In order to investigate the mode of action of these compounds, we have thus studied a number of biochemical parameters such as their resistance to phosphorolysis by intact human blood platelets or by recomAbbreviations used : HSV-1, herpes simplex virus type 1 ; HSV-2, herpes simplex virus type 2 ; VZV, varicella zoster virus ; CMV, cytomegalovirus ; VV, vaccinia virus ; VSV, vesicular-stomatitis virus ; TK, thymidine kinase ; TP, thymidine phosphorylase ; TS, thymidylate synthase ; UDG, uracil-DNA glycosylase (EC 3.2.2.3 ; systematic name uridine ribohydrolase) ; dU, 2h-deoxyuridine ; SdU, 4h-thio-2h-deoxyuridine ; Thd, thymidine ; SThd, 4h-thiothymidine ; EdU, 5-ethyl-2h-deoxyuridine, SEdU, 4h-thio-5-ethyl-2h-deoxyuridine ; IPdU, 5-isopropyl-2h-deoxyuridine ; SIPdU, 4h-thio-5-isopropyl-2h-deoxyuridine ; CPdU, 5-cyclopropyl-2h-deoxyuridine ; SCPdU, 4h-thio-5-cyclopropyl-2h-deoxyuridine ; t-BdU, 5-t-butyl-2h-deoxyuridine ; StBdU, 4h-thio-5-t-butyl-2h-deoxyuridine ; CBdU, 5-cyclobutyl-2h-deoxyuridine ; SCBdU, 4h-thio-5-cyclobutyl-2h-deoxyuridine ; CPedU, 5-cyclopentyl-2h-deoxyuridine ; SCPedU, 4h-thio-5-cyclopentyl-2h-deoxyuridine ; CHdU, 5-cyclohexyl-2h-deoxyuridine ; SCHdU, 4h-thio-5-cyclohexyl-2h-deoxyuridine ; BVdU, 5-bromovinyl-2h-deoxyuridine ; SBVdU, 4h-thio-5-bromovinyl-2h-deoxyuridine ; IdU, 5-iodo-2h-deoxyuridine ; SIdU, 4h-thio-5-iodo-2h-deoxyuridine ; HEL, human embryonic lung fibroblasts ; CCID 50 , 50 % cell culture infective dose ; DMEM, Dulbecco's modified Eagle's medium ; FCS, foetal-calf serum ; PFU, plaque-forming units ; MOI, multiplicity of infection. 1 This paper is dedicated to the late Professor R. T. Walker. 2 Present address : Melford Laboratories Ltd., Bildeston Rd. Chelsworth, Ipswich, Suffolk IP7 7LE, U.K. 3 Deceased. 4 To whom correspondence should be sent (e-mail spadari!igbe.pv.cnr.it).
2h-deoxyuridines are better inhibitors than their 4h-oxy counterparts of [$H]thymidine incorporation in HSV-1-infected cells ; (vi) 4h-thio-2h-deoxyuridines are not recognized by HSV-1 and human uracil-DNA glycosylases. Our data suggest that 4h-thio2h-deoxyuridines, resistant to pyrimidine phosphorylase, can be preferentially or selectively phosphorylated by viral TK in HSVinfected cells, where they are further converted into triphosphate by cellular nucleotide kinases. Once incorporated into viral DNA, they are better inhibitors of viral DNA synthesis than their corresponding 4h-oxy counterpart, either because they are not recognized, and thus not removed, by viral uracil-DNA glycosylase, or because they preferentially interfere with viral DNA polymerase.
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binant human thymidine phosphorylase (TP) and their ability to act as inhibitors and substrates for cellular and viral thymidine kinases (TKs). Two reference nucleosides were $H-labelled, thus allowing us to investigate whether they are phosphorylated to mono-and di-phosphate by herpes simplex virus type-1 (HSV-1) TK or if they are inhibitors of human thymidylate synthase (TS), human uracil-DNA glycosylase (UDG) and HSV-1 UDG and whether they are phosphorylated to 4h-thio-2h-deoxyribose triphosphate in infected cells, any or all of which may interfere with viral DNA polymerase and DNA synthesis. 
MATERIALS AND METHODS

Chemicals
Synthesis of nucleosides
The series of 5-substituted 4h-thio-2h-deoxyuridines was synthesized as previously described [7] .
Cells and virus assays
HeLa TK − cells (human epithelial cell line derived from a cervix carcinoma, TK-deficient) and HeLa TK − \HSV-1 TK + (HeLa TK − transformed to the TK + phenotype with a functional copy of the HSV-1 TK gene) were those previously used [3] . Cells were tested for mycoplasma contamination with the Hoechst 33258 staining method and were found to be negative. 
Cloning, expression and purification of human TP
The complete cloning of human TP has been extensively described by Focher et al. [9] . Briefly, TP cDNA, contained in plasmid pPL5 [10] (kindly provided by Professor R. Bicknell, Institute of Molecular Medicine, University of Oxford, Oxford, U.K.), was subcloned in pTrcHisC (Invitrogen, Leek, The Netherlands) to give the recombinant bacterial expression vector pHisTP containing the His-tagged TP sequence which encodes for a 509-amino-acid protein. His-tagged TP expression and purification were carried out as described by the manufacturer of the Ni-NTA (Ni# + -nitrilotriacetate) Superflow resin (Qiagen, Hilden, Germany).
TK assay
HSV-1 TK was purified and assayed as previously described [8] with some modifications. Briefly, the enzyme was incubated at 37 mC for 30 min in a mixture (25 µl) containing 30 mM potassium Hepes, pH 7.5, 6 mM MgCl # , 6 mM ATP, 0. [8] , was assayed under the same reaction conditions, but using [methyl-$H]dThd (sp. radioactivity 2200 c.p.m.\pmol) at 1.12 µM in place of 0.15 µM. The reaction was terminated by spotting 20 µl of the incubation mixture on a 25 mm-diameter DEAE-paper disk (DE-81 paper ; Whatman). The disks were processed and the radioactivity was counted as described in [8] .
Nucleoside degradation by recombinant human TP and by intact human blood platelets and HPLC analysis of the reaction products
A mixture (25 µl) containing 0.1 mM thymidine or 0.1 mM of the compound to be tested, 50 mM sodium arsenate, pH 6.2, and an amount of enzyme to give linear reaction rate was incubated at 37 mC for 30 min and then heated 5 min at 90 mC. The tube was then centrifuged at 9000 g for 5 min, the supernatant (20 µl) was then injected into the HPLC apparatus and analysed by the procedure described by Focher et al. [9] . The relative peak areas of thymine and thymidine were used to determine the enzymic activity of TP.
To determine the phosphorolysis of 4h-thio-and 4h-oxy-2h-deoxyuridines by intact human blood platelets, prepared as described by Desgranges et al. [11] , a sample of 3i10) platelets\ml was incubated at 37 mC in a mixture (350 µl) containing 10 mM Tris\HCl (pH 7.5), 1 mM sodium phosphate (pH 7.5), 0.15 M NaCl, 1 mM EDTA and 0.1 mM of the compound to be tested. At different times, 100 µl aliquots were removed, rapidly cooled on ice and centrifuged for 10 min at 3000 g at 4 mC. Sample of the supernatant (20 µl) was analysed by HPLC as described above.
TS assay : determination of 3 H release from [ 3 H]deoxycytidine
The activity of TS in HeLa and HeLa TK − \HSV-1 TK + cells was measured by estimation of $H released from [$H]deoxyuridylate (formed in the cells from [$H]deoxycytidine) in the reaction catalysed by TS [12] . A modified version of this method was followed [4] .
UDG assay
UDG activity was assayed as previously described [13] . Recombinant HSV-1 UDG was expressed and purified as previously described [14] , and human UDG was purified from HeLa cells as reported by Focher et al. [13] .
Effect of IPdU and SIPdU on viral DNA synthesis
HeLa TK − cells (1.2i10' at a concentration of 4.3i10&\ml) were seeded in a 30 mm-diameter Petri disk in DMEM and incubated at 37 mC. . Cells were further incubated 30 h. To each sample was added 2 ml of cold 10 % (w\v) trichloroacetic acid, and acid-precipitable radioactivity was bound on GF\C filters by filtering under vacuum. Filters were washed with 10 ml of cold 10 % TCA, then with ethanol and finally dried. Radioactivity was counted in a β-radiation counter after the addition of 1 ml of Betamax scintillation fluid (ICN, Costa Mesa, CA, U.S.A.) to each filter.
Extraction of 3 H-labelled nucleosides, nucleotides and DNA from HeLa TK − cells infected with HSV-1
HeLa TK − cells (1.2i10' at a concentration of 5.14i10&\ml) were seeded in 30 mm-diameter Petri dish in DMEM and incubated at 37 mC. After 16 h the medium was replaced with fresh medium and the virus (6i10' PFU\Petri dish ; MOI 5) was added. After 1 h cells were washed with PBS and re-suspended in 2 ml of fresh medium containing either 5 µM % and kept at room temperature for 30 min. Cell lysate was transferred in an Eppendorf tube and centrifuged for 10 min at 13 000 g. The pellet was stored at k20 mC and the supernatant was neutralized with 35 µl of 4 M KOH and 40 µl of 1 M potassium phosphate buffer, pH 7.4, centrifuged for 10 min at 12 000 rev.\min and freezedried overnight. To each sample 500 µl of 20 mM KH # PO % (pH 3)\20 % (v\v\) methanol was added. A 200 µl portion of this solution, containing labelled nucleosides and nucleotides, was injected into the HPLC apparatus (see below). The acidprecipitable radioactivity (total DNA) present in the pellet, previously stored at k20 mC, was resuspended in 900 µl of cold 0.5 M HClO % and heated 15 min at 80 mC. To an aliquot the liquid-scintillation fluid EcoLume (ICN, Costa Mesa, CA, U.S.A.) was added and the mixture counted for radioactivity in a β-radiation counter to determine the total radioactivity incorporated into DNA. An ion-exchange-chromatography method employing an HPLC system was used in order to separate nucleosides from nucleotides. A 4.6 mmi25 cm TSKgel DEAE-2SW column (TosoHaas, Montgomeryville, PA, U.S.A.) was used at room temperature with the following conditions : injection volume, 200 µl ; detection, UV 260 nm ; eluents, buffer
Gradient conditions : 50 min linear gradient from buffer A to B. The flow rate was 1 ml\min ; 50 fractions (fraction volume 1 ml) were collected and counted for radioactivity in a β-radiation counter after the addition of 4 ml of EcoLume to each sample. Table 2 reports the comparison of the antiviral activity of several 4h-thio-and 4h-oxy-2h-deoxyuridine analogues against HSV-1, HSV-2, VV and VSV, and Table 3 micromolar or nanomolar range. In particular, against HSVs the activity of 4h-thio-2h-deoxyuridines is significantly higher than that of their respective 4h-oxy counterparts. This is the case for SThd, SIPdU, 4h-thio-5-cyclopropyl-2h-deoxyuridine (SCPdU), whose IC &! values are, on average, 100-fold lower than their 4h-oxy counterparts with low or no cytostatic or cytotoxic activity (with the exception of SThd) against the cell lines used for these antiviral studies. This interesting behaviour shown by 4h-thio-2h-deoxyuridines against HSVs led us to study in itro the effect of some selected compounds on a number of HSV-1 and cellular enzymic activities with the aim of understanding the reasons for the higher antiviral activity of 4h-thio-2h-deoxyuridines compared with their 4h-oxy-counterparts.
RESULTS
Comparative analysis of antiviral and cytotoxic activity of 4h-thioand 4h-oxy-2h-deoxyuridines
4h-Thio-2h-deoxyuridines selectively inhibit thymidine phosphorylation catalysed by HSV-1 TK
We first studied the effect of several 4h-thio-2h-deoxyuridines (reported in Table 2 ) in comparison with their 4h-oxy counterparts, on the phosphorylation of [$H]Thd catalysed by HSV-1 and human TKs. Interestingly, all these compounds exert an inhibitory activity against the viral enzyme, while being inactive or much less potent against human TK (Table 4) . Each IC &! value presented in Table 4 is calculated from the curve of [I] (inhibitor concentration) plotted against 1\ (the reciprocal of the enzyme velocity) and represents the average for two experiments in which five different concentrations of the tested compound were used. S.D. never exceeded p20 % of each reported value.
Since 4h-thio-analogues, except SThd and, to a minor extent, SCPdU, do not inhibit [$H]Thd phosphorylation by human TK, we can argue that most of the 4h-thio analogues do not interact with the active site of the enzyme and are not phosphorylated to any significant extent by cellular TK. Moreover, when the 5-substituent remains fairly small (up to t-butyl) the 4h-thio analogues are powerful inhibitors of the phosphorylation of thymidine by HSV-1 TK and are likely to be acting as substrates. Both 4h-oxy-and 4h-thio-2h-deoxyuridines competitively inhibit viral TK, suggesting a specific interaction of these compounds with the active site of the viral enzyme. In particular, IPdU and SIPdU show K i values of 0.3 and 0.09 µM respectively.
IPdU and SIPdU are phosphorylated by HSV-1 TK to mono-and di-phosphate
To determine whether IPdU and SIPdU are substrate inhibitors of the viral enzyme or pure non-substrate inhibitors, we incubated HSV-1 TK with [$H]IPdU and [$H]SIPdU as described in the Materials and methods section. Figure 1 shows that, under the assay conditions reported in the Materials and methods section, which are optimal for the phosphorylation of the natural substrate, Thd (K m 0.25 µM), both IPdU and SIPdU are phosphorylated by the HSV-1 TK. The enzyme shows similar K m values for both compounds (0.6 µM), but different V max values (1.9 and 5 pmol\30 min for IPdU and SIPdU respectively) ; this indicates that, under our in itro assay conditions, SIPdU is 2.6-fold more phosphorylated than IPdU. In order to determine whether the enzyme is also able to phosphorylate both compounds to the diphosphate form, as is the case for the natural substrate, Thd, the products of the reaction were resolved by HPLC as described in the Materials and methods section. Table  5 shows a comparison of the enzymic products of the reaction in which [$H]IPdU or [$H]SIPdU were used as substrates. In both cases HSV-1 TK is able to phosphorylate these uridine derivatives up to the diphosphate form, with a preference for the 4h-oxy derivative.
4h-Thio-2h-deoxyuridines are resistant to phosphorolysis by recombinant human thymidine phosphorylase and by intact human blood platelets
We then studied whether 4h-oxy-and 4h-thio-2h-deoxyuridines, like Thd, are bona fide substrates of human TP and we found that, under conditions where an excess of purified recombinant TP completely transforms 2 µmol of Thd to thymine in 15 min, all the 4h-thio-2h-deoxyuridines described in the present study were completely resistant to degradation (results not shown). Among the 4h-oxy-2h-deoxyuridines, only the compounds with small 5-substituents (such as methyl, ethyl, bromovinyl) were sensitive to the enzyme (Figure 2A) .
In order to address the same question by using a natural system, we prepared human intact blood platelets [11] , known to contain high levels of TP. In this system it was previously found that several 5-substituted 2h-deoxyuridines are degraded by TP, a fact that limits their potential therapeutic activity [15] . To compare the susceptibility of 4h-oxy-and 4h-thio-2h-deoxyuridines in this system, we incubated intact human blood platelet with H]uridylate in cells exposed to deoxy 
Figure 3 Effect of IPdU (#) and SIPdU ($) on tritium release by TS from deoxy
H]cytidine
Each point is the average of three determinations.
0.1 mM Thd, IPdU, 5-cyclopropyl-2h-deoxyuridine (CPdU) and BVdU or their corresponding 4h-thio counterparts as described in the Materials and methods section. Aliquots of the incubation mixture were removed at 0, 1, 10 and 24 h and analysed by HPLC. Also under these assay conditions all the 4h-thio-2h-deoxyuridines tested were found to be fully resistant to enzymic degradation ( Figure 2B ), but, surprisingly, among the corresponding 4h-oxy-2h-deoxyuridines previously found resistant to degradation by recombinant TP, IPdU was partially hydrolysed. Thus its observed resistance to degradation by recombinant TP (even at 10-fold higher enzyme concentrations ; results not shown) might suggest that other enzymic activities could be involved in its in i o catabolism.
In vivo effect of IPdU and SIPdU on TS activity
It is known that several 5-substituted dUMP analogues, such as 5-fluoro-dUMP and 5-bromovinyl-dUMP, are potent inhibitors of cellular TS [16] . This inhibition depletes the dTTP pool in infected cells, directly affecting DNA synthesis and contributing to their cytotoxicity. Therefore we investigated and compared the effect of IPdU and SIPdU on TS activity in HeLa TK − \HSV-1 TK + cells. TS represents the de no o pathway of dTMP synthesis, since it catalyses the reductive methylation of dUMP to dTMP, in which the hydrogen atom on C-5 of the uracil ring is replaced by a methyl group. Thus the activity of TS in intact cells can be measured by estimating the $H release from 
Effect of 4h-thio-and 4h-oxy-2h-deoxyuridine analogues on human and HSV-1 UDGs
When some deoxyuridine analogues reported in Table 4 were assayed in itro against HSV-1 recombinant UDG and human UDG, the 4h-thio-2h-deoxyuridines tested were found inactive against both enzymes. On the other hand, the 4h-oxy-2h-deoxyuridines CPdU and IPdU were able to inhibit HSV-1 and human UDGs with a strong preference for the viral enzyme. The corresponding modified bases were inactive (results not shown). This might imply that, in contrast with the 4h-oxy-, the modified 4h-thio-2h-deoxyuridines, once incorporated into viral DNA by viral DNA polymerase, are not recognized by the viral UDG and would not be removed, thus increasing their antiviral potency. Cells were further incubated 6 h, when viral TK is maximally expressed, and then extensively washed in PBS (90 % of the labelled material is removed in this step). From the cell pellets the remaining radioactivity was extracted as described in the Materials and methods section. As reported in Table 6 , very low levels of labelled nucleosides were present in the cell extracts ; this indicates both a lack of contamination of extracellular labelled material and the complete phosphorylation of the nucleosides once incorporated into the cells. The data reported in 
Fate of 4h-thio-and 4h-oxy-2h-deoxyuridines in HSV-1 infected cells
When
DISCUSSION
In order to improve the biological activity of 2h-deoxynucleoside analogues as anticancer and antiviral agents it has been thought important to decrease their susceptibility to degradation by nucleoside phosphorylase. To this purpose, chemical modifications of the sugar ring, such as replacement of the 4h-oxygen by a methylene group [1, 2] or replacement of the -2h-deoxyribose or the carbocyclic -2h-deoxyribose by their respective  enantiomers [3] [4] [5] have indeed given rise to nucleosides resistant to such degradation and which remain active as anticancer and antiviral agents [17] . Replacement of the 4h-oxygen by sulphur was also studied, but only in the case of ribonucleosides [18] . On the basis of the finding that the 4h-thio modification introduced in ribonucleosides conferred resistance to nucleoside cleavage as well, only a few deoxyribonucleosides, such as 2h-deoxy-5-fluoro4h-thiouridine [19] , SThd [20, 21] and SBVdU [20] [21] [22] , have been synthesized and tested against HSV infections. These compounds showed potent antiviral activity against HSV-1 and CMV, but still possess severe cytotoxicity [19] [20] [21] [22] . Thus a novel series of 5-substituted 4h-thio-2h-deoxypyrimidines were synthesized and evaluated for their potential anti-HSV activity [7] . In the present work we have compared the antiviral activity of these compounds with their 4h-oxy counterparts and have interestingly found that all 4h-thio-2h-deoxyuridines are not only more active against HSV-1, HSV-2 and VZV than their 4h-oxy counterparts but also poorly or not cytotoxic against mammalian cells. In order to define their chemotherapeutic potential, in the present study we also evaluated their effect on a number of viral and cellular enzymic activities. We thus demonstrated that the higher efficacy of the 4h-thio-2h-deoxyuridines as anti-herpetic agents compared with their 4h-oxy counterparts could be based not only their higher affinity for HSV-1 TK, which selectively phosphorylates them to the mono-and di-phosphate form (the triphosphate is then made by cellular enzymes), but also upon their resistance to phosphorolysis by human TP. 4h-Thio-2h-deoxyuridines were indeed resistant to phosphorolysis by recombinant TP or by intact blood platelets, whereas the most active 4h-oxy counterparts, being those which possess small substituents in position 5 (methyl, ethyl, cyclopropyl and bromovinyl), were all substrates for human TP. Those with more bulky 5-substituents become progressively more resistant to phosphorolysis, but show lower antiviral activity because they are poorer substrates for viral TK.
Furthermore, the higher efficacy of some 4h-thio-2h-deoxyuridines as anti-herpetic agents compared with their 4h-oxy counterparts could be also explained by the fact that the 4h-thio2h-deoxyuridines, in contrast with their corresponding 4h-oxy-2h-deoxyuridines, are not recognized by HSV-1 and human UDGs. This suggests that the 4h-thio-2h-deoxyuridines do not affect postreplicative base excision repair in replication foci [23] in noninfected cells. However, it is also possible that, once incorporated into viral genome by viral DNA polymerase, 4h-thio-2h-deoxyuridines might not be recognized nor removed by cellular or viral UDGs, thus interfering with viral DNA replication and transcription.
We also found that both 4h-oxy-and 4h-thio-2h-deoxyuridines, in the phosphorylated form, are inhibitors of cellular thymidylate synthase. This indicates that they affect the de no o synthesis of TMP only in HSV-1-infected cells, but do not interfere with cellular TS activity in non-infected cells, where they are not present in the monophosphate form because of the absence of viral TK.
The results of the present study support our hypothesis that 4h-thio-2h-deoxyuridines have a potential chemotherapeutic use as antiviral agents and may help to rationalize their target specificity.
